The only two FDA-approved treatments currently available for NF1 patients—both targeting MEK signaling—were approved in the USA within the last five years, marking a 30-year gap between the identification of MEK as a therapeutic target and the eventual approval of effective drugs [31,32,33]. Here, MAP2K7 is linked to neurofibromatosis type 1.